US Breast cancer Market

ID: MRFR/Pharma/16386-HCR
100 Pages
Satyendra Maurya
Last Updated: April 06, 2026
United States Breast cancer Market Research Report: Size, Share, Trend Analysis - Growth Outlook & Industry Forecast 2025 To 2035
US Breast cancer Market
Market Size
Forecast Period2025 - 2035
CAGR (2025 - 2035)8.35%
2024 Market Size$ 1,025.25 Million
2025 Market Size$ 1,119.78 Million
2035 Market Size$ 2,476.57 Million
Key Players
AbbVie Inc
Amgen Inc
Bristol-Myers Squibb Company
Genentech Inc
Johnson & Johnson
Merck & Co Inc
Trends
  • Rise of Personalized Medicine
  • Advancements in Early Detection Technologies
  • Increased Focus on Patient Advocacy and Support
Opportunities
  • Emergence of Telehealth Services
  • Government Initiatives and Funding
  • Growing Incidence of Breast Cancer
Summary Table of Contents Segmentation Download PDF
  1. 1 SECTION I: EXECUTIVE SUMMARY AND KEY HIGHLIGHTS
    1. 1.1 EXECUTIVE SUMMARY
      1. 1.1.1 Market Overview
      2. 1.1.2 Key Findings
      3. 1.1.3 Market Segmentation
      4. 1.1.4 Competitive Landscape
      5. 1.1.5 Challenges and Opportunities
      6. 1.1.6 Future Outlook
  2. 2 SECTION II: SCOPING, METHODOLOGY AND MARKET STRUCTURE
    1. 2.1 MARKET INTRODUCTION
      1. 2.1.1 Definition
      2. 2.1.2 Scope of the study
        1. 2.1.2.1 Research Objective
        2. 2.1.2.2 Assumption
        3. 2.1.2.3 Limitations
    2. 2.2 RESEARCH METHODOLOGY
      1. 2.2.1 Overview
      2. 2.2.2 Data Mining
      3. 2.2.3 Secondary Research
      4. 2.2.4 Primary Research
        1. 2.2.4.1 Primary Interviews and Information Gathering Process
        2. 2.2.4.2 Breakdown of Primary Respondents
      5. 2.2.5 Forecasting Model
      6. 2.2.6 Market Size Estimation
        1. 2.2.6.1 Bottom-Up Approach
        2. 2.2.6.2 Top-Down Approach
      7. 2.2.7 Data Triangulation
      8. 2.2.8 Validation
  3. 3 SECTION III: QUALITATIVE ANALYSIS
    1. 3.1 MARKET DYNAMICS
      1. 3.1.1 Overview
      2. 3.1.2 Drivers
      3. 3.1.3 Restraints
      4. 3.1.4 Opportunities
    2. 3.2 MARKET FACTOR ANALYSIS
      1. 3.2.1 Value chain Analysis
      2. 3.2.2 Porter's Five Forces Analysis
        1. 3.2.2.1 Bargaining Power of Suppliers
        2. 3.2.2.2 Bargaining Power of Buyers
        3. 3.2.2.3 Threat of New Entrants
        4. 3.2.2.4 Threat of Substitutes
        5. 3.2.2.5 Intensity of Rivalry
      3. 3.2.3 COVID-19 Impact Analysis
        1. 3.2.3.1 Market Impact Analysis
        2. 3.2.3.2 Regional Impact
        3. 3.2.3.3 Opportunity and Threat Analysis
  4. 4 SECTION IV: QUANTITATIVE ANALYSIS
    1. 4.1 Healthcare, BY Diagnosis Method (USD Million)
      1. 4.1.1 Mammography
      2. 4.1.2 Ultrasound
      3. 4.1.3 Magnetic Resonance Imaging
      4. 4.1.4 Biopsy
      5. 4.1.5 Genetic Testing
    2. 4.2 Healthcare, BY Treatment Type (USD Million)
      1. 4.2.1 Surgery
      2. 4.2.2 Radiation Therapy
      3. 4.2.3 Chemotherapy
      4. 4.2.4 Hormonal Therapy
      5. 4.2.5 Targeted Therapy
    3. 4.3 Healthcare, BY Stage of Cancer (USD Million)
      1. 4.3.1 Stage 0
      2. 4.3.2 Stage I
      3. 4.3.3 Stage II
      4. 4.3.4 Stage III
      5. 4.3.5 Stage IV
    4. 4.4 Healthcare, BY Patient Demographics (USD Million)
      1. 4.4.1 Age Group
      2. 4.4.2 Ethnicity
      3. 4.4.3 Socioeconomic Status
      4. 4.4.4 Genetic Predisposition
      5. 4.4.5 Family History
    5. 4.5 Healthcare, BY Healthcare Setting (USD Million)
      1. 4.5.1 Hospital
      2. 4.5.2 Outpatient Clinic
      3. 4.5.3 Specialized Cancer Center
      4. 4.5.4 Home Healthcare
      5. 4.5.5 Palliative Care
  5. 5 SECTION V: COMPETITIVE ANALYSIS
    1. 5.1 Competitive Landscape
      1. 5.1.1 Overview
      2. 5.1.2 Competitive Analysis
      3. 5.1.3 Market share Analysis
      4. 5.1.4 Major Growth Strategy in the Healthcare
      5. 5.1.5 Competitive Benchmarking
      6. 5.1.6 Leading Players in Terms of Number of Developments in the Healthcare
      7. 5.1.7 Key developments and growth strategies
        1. 5.1.7.1 New Product Launch/Service Deployment
        2. 5.1.7.2 Merger & Acquisitions
        3. 5.1.7.3 Joint Ventures
      8. 5.1.8 Major Players Financial Matrix
        1. 5.1.8.1 Sales and Operating Income
        2. 5.1.8.2 Major Players R&D Expenditure. 2023
    2. 5.2 Company Profiles
      1. 5.2.1 Roche (CH)
        1. 5.2.1.1 Financial Overview
        2. 5.2.1.2 Products Offered
        3. 5.2.1.3 Key Developments
        4. 5.2.1.4 SWOT Analysis
        5. 5.2.1.5 Key Strategies
      2. 5.2.2 Pfizer (US)
        1. 5.2.2.1 Financial Overview
        2. 5.2.2.2 Products Offered
        3. 5.2.2.3 Key Developments
        4. 5.2.2.4 SWOT Analysis
        5. 5.2.2.5 Key Strategies
      3. 5.2.3 AstraZeneca (GB)
        1. 5.2.3.1 Financial Overview
        2. 5.2.3.2 Products Offered
        3. 5.2.3.3 Key Developments
        4. 5.2.3.4 SWOT Analysis
        5. 5.2.3.5 Key Strategies
      4. 5.2.4 Novartis (CH)
        1. 5.2.4.1 Financial Overview
        2. 5.2.4.2 Products Offered
        3. 5.2.4.3 Key Developments
        4. 5.2.4.4 SWOT Analysis
        5. 5.2.4.5 Key Strategies
      5. 5.2.5 Merck & Co (US)
        1. 5.2.5.1 Financial Overview
        2. 5.2.5.2 Products Offered
        3. 5.2.5.3 Key Developments
        4. 5.2.5.4 SWOT Analysis
        5. 5.2.5.5 Key Strategies
      6. 5.2.6 Bristol-Myers Squibb (US)
        1. 5.2.6.1 Financial Overview
        2. 5.2.6.2 Products Offered
        3. 5.2.6.3 Key Developments
        4. 5.2.6.4 SWOT Analysis
        5. 5.2.6.5 Key Strategies
      7. 5.2.7 Gilead Sciences (US)
        1. 5.2.7.1 Financial Overview
        2. 5.2.7.2 Products Offered
        3. 5.2.7.3 Key Developments
        4. 5.2.7.4 SWOT Analysis
        5. 5.2.7.5 Key Strategies
      8. 5.2.8 Eli Lilly and Company (US)
        1. 5.2.8.1 Financial Overview
        2. 5.2.8.2 Products Offered
        3. 5.2.8.3 Key Developments
        4. 5.2.8.4 SWOT Analysis
        5. 5.2.8.5 Key Strategies
      9. 5.2.9 Amgen (US)
        1. 5.2.9.1 Financial Overview
        2. 5.2.9.2 Products Offered
        3. 5.2.9.3 Key Developments
        4. 5.2.9.4 SWOT Analysis
        5. 5.2.9.5 Key Strategies
    3. 5.3 Appendix
      1. 5.3.1 References
      2. 5.3.2 Related Reports
  6. 6 LIST OF FIGURES
    1. 6.1 MARKET SYNOPSIS
    2. 6.2 US MARKET ANALYSIS BY DIAGNOSIS METHOD
    3. 6.3 US MARKET ANALYSIS BY TREATMENT TYPE
    4. 6.4 US MARKET ANALYSIS BY STAGE OF CANCER
    5. 6.5 US MARKET ANALYSIS BY PATIENT DEMOGRAPHICS
    6. 6.6 US MARKET ANALYSIS BY HEALTHCARE SETTING
    7. 6.7 KEY BUYING CRITERIA OF HEALTHCARE
    8. 6.8 RESEARCH PROCESS OF MRFR
    9. 6.9 DRO ANALYSIS OF HEALTHCARE
    10. 6.10 DRIVERS IMPACT ANALYSIS: HEALTHCARE
    11. 6.11 RESTRAINTS IMPACT ANALYSIS: HEALTHCARE
    12. 6.12 SUPPLY / VALUE CHAIN: HEALTHCARE
    13. 6.13 HEALTHCARE, BY DIAGNOSIS METHOD, 2024 (% SHARE)
    14. 6.14 HEALTHCARE, BY DIAGNOSIS METHOD, 2024 TO 2035 (USD Million)
    15. 6.15 HEALTHCARE, BY TREATMENT TYPE, 2024 (% SHARE)
    16. 6.16 HEALTHCARE, BY TREATMENT TYPE, 2024 TO 2035 (USD Million)
    17. 6.17 HEALTHCARE, BY STAGE OF CANCER, 2024 (% SHARE)
    18. 6.18 HEALTHCARE, BY STAGE OF CANCER, 2024 TO 2035 (USD Million)
    19. 6.19 HEALTHCARE, BY PATIENT DEMOGRAPHICS, 2024 (% SHARE)
    20. 6.20 HEALTHCARE, BY PATIENT DEMOGRAPHICS, 2024 TO 2035 (USD Million)
    21. 6.21 HEALTHCARE, BY HEALTHCARE SETTING, 2024 (% SHARE)
    22. 6.22 HEALTHCARE, BY HEALTHCARE SETTING, 2024 TO 2035 (USD Million)
    23. 6.23 BENCHMARKING OF MAJOR COMPETITORS
  7. 7 LIST OF TABLES
    1. 7.1 LIST OF ASSUMPTIONS
  8. 7.1.1
    1. 7.2 US MARKET SIZE ESTIMATES; FORECAST
      1. 7.2.1 BY DIAGNOSIS METHOD, 2026-2035 (USD Million)
      2. 7.2.2 BY TREATMENT TYPE, 2026-2035 (USD Million)
      3. 7.2.3 BY STAGE OF CANCER, 2026-2035 (USD Million)
      4. 7.2.4 BY PATIENT DEMOGRAPHICS, 2026-2035 (USD Million)
      5. 7.2.5 BY HEALTHCARE SETTING, 2026-2035 (USD Million)
    2. 7.3 PRODUCT LAUNCH/PRODUCT DEVELOPMENT/APPROVAL
  9. 7.3.1
    1. 7.4 ACQUISITION/PARTNERSHIP
  10. 7.4.1

US Breast cancer Market Segmentation

US Breast cancer Market By Diagnosis Method (USD Million, 2022-2035)

  • Mammography
  • Ultrasound
  • Magnetic Resonance Imaging
  • Biopsy
  • Genetic Testing

US Breast cancer Market By Treatment Type (USD Million, 2022-2035)

  • Surgery
  • Radiation Therapy
  • Chemotherapy
  • Hormonal Therapy
  • Targeted Therapy

US Breast cancer Market By Stage of Cancer (USD Million, 2022-2035)

  • Stage 0
  • Stage I
  • Stage II
  • Stage III
  • Stage IV

US Breast cancer Market By Patient Demographics (USD Million, 2022-2035)

  • Age Group
  • Ethnicity
  • Socioeconomic Status
  • Genetic Predisposition
  • Family History

US Breast cancer Market By US Breast cancer Market Setting (USD Million, 2022-2035)

  • Hospital
  • Outpatient Clinic
  • Specialized Cancer Center
  • Home US Breast cancer Market
  • Palliative Care

Related Reports

No regional reports available for this market.

No country-specific reports available for this market.

Customer Stories

Case Study Cover Image
Case Study

Aerospace & Defense

Future of Dismounted Soldier Systems Market Trends & Adoption Roadmap 2019–2035
Download PDF ×

We do not share your information with anyone. However, we may send you emails based on your report interest from time to time. You may contact us at any time to opt-out.